Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients

Heart

Volumn 98, Issue 24, 2012, Pages 1812-1816

  Nerla, Roberto ^a   Di Franco, Antonino ^a   Milo, Maria ^a   Pitocco, Dario ^a   Zaccardi, Francesco ^a,b   Tarzia, Pierpaolo ^b   Sarullo, Filippo Maria ^b   Villano, Angelo ^a   Russo, Giulio ^a   Stazi, Alessandra ^a   Ghirlanda, Giovanni ^a   Lanza, Gaetano Antonio ^a   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Buccheri la Ferla Fatebenefratelli Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; IVABRADINE; PLACEBO;

ADULT; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTICLE; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; FEMALE; FLOW MEDIATED DILATION; HEART AUTOMATICITY; HEART RATE; HEART RATE VARIABILITY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NITRATE MEDIATED DILATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNIVERSITY HOSPITAL; VASODILATATION;

ATENOLOL; BENZAZEPINES; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS; VASODILATION;

EID: 84870416330     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302795     Document Type: Article

References (32)

1. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007;50:823-30. (Pubitemid 47277500)
2. Lanza GA, Fox K, Crea F. Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing. Adv Cardiol 2006;43:1-16. (Pubitemid 44290159)
3. Kannel WB, Kannel C, Paffenbarger RS Jr, et al. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J 1987;113:1489-94. (Pubitemid 17092823)
4. Seccareccia F, Pannozzo F, Dima F, et al. Heart rate as a predictor of mortality: the MATISS project. Am J Public Health 2001;91:1258-63. (Pubitemid 32708866)
5. Hjalmarson A, Gilpin EA, Kjekshus J, et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990;65:547-53. (Pubitemid 20091878)
6. Custodis F, Schirmer SH, Baumhäkel M, et al. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 2010;56:1973-83.
7. Bank AJ, Kelly AS, Thelen AM, et al. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens 2007;20:777-83. (Pubitemid 46936169)
8. Flammer AJ, Hermann F, Wiesli P, et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 2007;25:785-91. (Pubitemid 46398873)
9. Heffernan KS, Suryadevara R, Patvardhan EA, et al. Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension. Clin Cardiol 2011;34:39-44.
10. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003;41:1281-6. (Pubitemid 36706078)
11. Fratta Pasini A, Garbin U, Nava MC, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005;23:589-96. (Pubitemid 40684718)
12. Di Francesco D, Camm AJ. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease. Drugs 2004;64:1757-65. (Pubitemid 39215187)
13. Custodis F, Baumhäkel M, Schlimmer N, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008;117:2377-87. (Pubitemid 351653554)
14. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34. (Pubitemid 28350165)
15. Hillis GS, Woodward M, Rodgers A, et al. Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia 2012;55:1283-90.
16. Ravikumar R, Deepa R, Shanthirani C, et al. Comparison of carotid intima-media thickness, arterial stiffness, and brachial artery flow mediated dilatation in diabetic and nondiabetic subjects (The Chennai Urban Population Study (CUPS-9)). Am J Cardiol 2002;90:702-7. (Pubitemid 35279388)
17. Ghiadoni L, Faita F, Salvetti M, et al. Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study. J Hypertens 2012;30:1399-405.
18. Nerla R, Tarzia P, Sestito A, et al. Effect of bariatric surgery on peripheral flow-mediated dilation and coronary microvascular function. Nutr Metab Cardiovasc Dis 2012;22:626-34.
19. Gemignani V, Faita F, Ghiadoni L, et al. A system for real-time measurement of the brachial artery diameter in B-mode ultrasound images. IEEE Trans Med Imaging 2007;26:393-404. (Pubitemid 46392347)
20. Lanza GA, Cianflone D, Rebuzzi AG, et al. Prognostic value of ventricular arrhythmias and heart rate variability in patients with unstable angina. Heart 2006;92:1055-63. (Pubitemid 44125216)
21. Vita JA. Endothelial function. Circulation 2011;124:e906-12.
22. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009;120:502-9.
23. Karatzis EN, Ikonomidis I, Vamvakou GD, et al. Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation. Am J Cardiol 2006;98:1424-8. (Pubitemid 44779467)
24. Kitta Y, Obata JE, Nakamura T, et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol 2009;53:323-30.
25. Bonaventura D, Lunardi CN, Rodrigues GJ, et al. Endothelium negatively modulates the vascular relaxation induced by nitric oxide donor, due to uncoupling NO synthase. J Inorg Biochem 2009;103:1366-74.
26. Davies PF. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat Clin Pract Cardiovasc Med 2009;6:16-26.
27. Brooks AR, Lelkes PI, Rubanyi GM. Gene expression profiling of human aortic endothelial cells exposed to disturbed flow and steady laminar flow. Physiol Genomics 2002;9:27-41. (Pubitemid 135707410)
28. Benjamin EJ, Larson MG, Keyes MJ, et al. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 2004;109:613-19. (Pubitemid 38198868)
29. Fox K, Ford I, Steg PG, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009;30:2337-45.
30. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85.
31. Lanza GA, Pitocco D, Navarese EP, et al. Association between cardiac autonomic dysfunction and inflammation in type 1 diabetic patients: effect of beta-blockade. Eur Heart J 2007;28:814-20. (Pubitemid 47343595)
32. Kaplan JR, Manuck SB. Antiatherogenic effects of beta-adrenergic blocking agents: theoretical, experimental, and epidemiologic considerations. Am Heart J 1994;128:1316-28.